The Global Cardiometabolic Risk Profile in Patients with hypertension disease (GOOD) survey investigated the global cardiometabolic risk profile in 3464 adult outpatients with hypertension across 289 sites in 12 European countries. The pulse pressure and heart rate profile of the survey population was evaluated according to the presence or absence of metabolic syndrome and/or type 2 diabetes mellitus. History and treatment of hypertension were not counted as criteria for metabolic syndrome as they applied to all patients. Out of the 3370 recruited patients, 1033 had metabolic syndrome and 1177 had neither metabolic syndrome nor diabetes. When compared with patients with no metabolic syndrome or diabetes, patients with metabolic syndrome had higher pulse pressure (59±14 vs 55±14 mm Hg) and heart rate (75.2±11.0 vs 72.5±10.0 beats per min) (Po0.001 for both), independent of the concomitant presence or absence of diabetes, despite a more prevalent use of b-blockers. In conclusion, in hypertensive outpatients the presence of metabolic syndrome is associated with increased heart rate and pulse pressure, which may at least in part reflect increased arterial stiffness and increased sympathetic tone. This may contribute, to some extent, to explaining the increased cardiovascular risk attributed to the presence of metabolic syndrome.
INTRODUCTION
Several epidemiological studies support resting heart rate as a predictor of total mortality and cardiovascular mortality in the general population, in coronary artery disease (CAD), and in hypertensive patients. [1] [2] [3] [4] [5] Heart rate appears to be a risk marker for cardiovascular mortality independent of other risk factors. Pulse pressure is also a risk factor, probably as a marker of central artery stiffness, 6, 7 and it has been suggested that lowering pulse pressure may be a useful predictor of the effectiveness of antihypertensive drug therapy. 8 Metabolic syndrome and diabetes are undoubtedly recognized as major cardiovascular risk factors, although the mechanisms are very complex and incompletely characterized. Although hypertension is widely acknowledged as a significant global health challenge, hypertension control rates are poor despite the availability of many effective antihypertensive treatments. [9] [10] [11] [12] We previously showed that less than a third of treated hypertensive patients in Europe achieve blood pressure control as recommended by European Society of Hypertension/European Society of Cardiology guidelines. 13 Moreover, the extent of blood pressure control was adversely influenced by the presence of metabolic syndrome and/or type 2 diabetes. 14 Recent data indicate that pulse pressure and heart rate in treated hypertensive patients are affected by the presence of metabolic syndrome and obesity. 15 In patients with metabolic syndrome, higher pulse pressure was hypothesized to reflect increased large artery stiffness, thereby contributing to cardiovascular risk. 16 Increased pulse pressure has been attributed to the effect of increased heart rate and attenuated pulse wave reflection. 17 The observation of an increased progression of aortic stiffness with age has led to the suggestion of premature senescence of large arteries in the presence of metabolic syndrome. 7 Aim of the study With this background, we evaluated the pulse pressure and heart rate profile in a large cohort of hypertensive outpatients in 12 countries across Europe according to the presence or absence of metabolic syndrome and/or diabetes. Blood pressure control was defined according to the European Society of Hypertension/ European Society of Cardiology guidelines.
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MATERIALS AND METHODS
Study design and patient criteria
The Global Cardiometabolic Risk Profile in Patients with hypertension disease (GOOD) survey was a Pan-European, observational, cross-sectional survey conducted in 305 sites in 12 European countries, between 6 October 2006 and 16 May 2007, as described previously. 13, 19 Participating countries were Belgium, Germany, Hungary, Italy, The Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Turkey and the UK. Investigators were randomly selected from two lists of practitioners containing from three to ten-fold the number of investigators needed, one for general practitioners (70% of investigators) and the other for specialists (30% of investigators, cardiologists, internists and hypertension specialists).
Data collection
The following assessments were made during the patient's visit: measurement of weight, height, waist circumference, seated-blood pressure, pulse pressure and heart rate at rest (two measurements taken after at least 3 min rest according to the European Society of Hypertension/ European Society of Cardiology guidelines. 13 ). The investigator also collected information on demographics and cardiometabolic risk factors including: duration of hypertension; history of diabetes, cardiovascular disease, or stroke; lifestyle factors including alcohol consumption, physical exercise and smoking habits, and laboratory measurements of fasting blood glucose, fasting lipid profile and serum creatinine data (provided from the patient's file if data had been collected within the previous 6 months). Information on current antihypertensive medications and other current chronic drug therapies, including cardiovascular drugs; lipid, glucose and uric acid-lowering drugs, and antithrombotic treatment was also obtained. There was no selective exclusion of patients with incomplete records.
Metabolic syndrome was defined according to ATP III criteria, 20 (that is, three or more of the following: blood pressure X130/85 mm Hg; waist circumference X102 cm (men) or X88 cm (women); triglycerides X1.69 mmol l À 1 or on drug treatment for elevated triglycerides; high density lipoprotein cholesterol o1.03 mmol l À 1 (men) or o1.29 mmol l À 1 (women) or on drug treatment for reduced high-density lipoprotein cholesterol; fasting glucoseX5.55 mmol l À 1 ) or on drug treatment for elevated glucose. In this study, history or treatment of hypertension were not counted as criteria for metabolic syndrome as they applied to all patients. Therefore, two of the other criteria were needed to fulfill the metabolic syndrome definition.
Statistics
The sample size estimation was defined at regional level and based on the 95% confidence interval of the frequency of risk factors. Assuming a frequency of risk factors around 50% and a precision of the 95% confidence interval between 3-4%, the sample size needed per geographical region was between 600 and 1100 patients per region. All patients with evaluable data regarding age, gender, blood pressure, pulse pressure, heart rate and antihypertensive treatment were included in the analysis. Comparisons between variables were made using a w 2 test for qualitative variables and Student's t-test or Wilcoxon for qualitative variables. Comparisons between variables for participants with no diabetes or metabolic syndrome, with diabetes only, with metabolic syndrome only or with diabetes and metabolic syndrome were made using analysis of variance models with adjustment on age, sex and b-blocker use. Comparisons between patients with diabetes and with no diabetes were also adjusted for the presence of metabolic syndrome, and comparisons between patients with metabolic syndrome and with no metabolic syndrome were adjusted for the presence of diabetes. P-Values o0.05 were considered significant.
Ethics
The study was conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all subsequent amendments. The study was also conducted in accordance with the European guidelines for GOOD Epidemiology Practice (GEP), and Proper Conduct in Epidemiologic Research (European Federation, International Epidemiological Association (IEA), and 'societies', 2004). Each participating country ensured that all necessary regulatory submissions (for example, Institutional Review Board (IRB)) were performed in accordance with local regulations including local data protection regulations.
RESULTS
In total, 3464 outpatients were recruited in the survey and of these, 3370 were included in the analyses. The main reasons for exclusion from the analyses were lack of informed consent (0.9%) and type 1 rather than type 2 diabetes mellitus (1.2%).
The characteristics of the survey participants, including heart rate, pulse pressure, blood pressure, blood pressure control and previous antihypertensive treatment, are shown in Table 1 . In the total study population, 57.8% had metabolic syndrome, 32.3% had type 2 diabetes and 25.6% had both metabolic syndrome and type 2 diabetes. As shown previously, blood pressure control was worse in patients with diabetes and metabolic syndrome. 13 Moreover, the prevalence of each of the five components of the metabolic syndrome was significantly greater in patients with uncontrolled blood pressure (66.5% vs 35.5%, respectively, Po0.001).
13 Patients with metabolic syndrome had higher systolic blood pressure, diastolic blood pressure, pulse pressure and heart rate. These parameters were independent of the Pulse pressure and heart rate in metabolic syndrome S Perlini et al concomitant presence or absence of diabetes. Although the patients with diabetes were older and more frequently males, pulse pressure was lower in the diabetic group than in patients with metabolic syndrome. A higher heart rate and pulse pressure was observed in patients with metabolic syndrome and in patients with metabolic syndrome with concomitant diabetes, despite a more prevalent use of b-blockers. The higher prevalence of calcium channel blocker use in patients with metabolic syndrome (owing to the need of treating uncontrolled hypertension, rather than to treat diagnosed CAD, according to the study investigators) did not influence the observed results. The overall prevalence of congestive heart failure and of CAD, that is, two clinical conditions that may influence the baroreflex control of heart rate, 21-23 were 5.4% and 15.2%, respectively, without any difference between patients with (n ¼ 1897) or without (n ¼ 1383) metabolic syndrome. As to drug use, no difference was reported in the prevalence of calcium channel blocker use either in congestive heart failure (P ¼ 0.294) or in CAD (P ¼ 0.070) patients. As expected, congestive heart failure patients were more likely to be treated with diuretics (Po0.001). This was not the case in CAD patients (P ¼ 0.183). The prevalence of renal insufficiency (creatinine clearanceo60 ml min À 1 ) was 12.9%, associated with a higher use of calcium channel blockers (P ¼ 0.035).
Adjusted analyses Heart rate and pulse pressure were adjusted for age, sex, and use of b-blockers, as these parameters differed in the groups according to the absence or presence of diabetes and metabolic syndrome (Po0.001). The results are given in Figures 1 and 2 . With this adjusted analysis, heart rate was highest in patients with metabolic syndrome and diabetes, and pulse pressure was higher in patients with metabolic syndrome with or without diabetes.
All pairwise comparisons between groups for heart rate were significant, except for diabetes alone compared with no diabetes or metabolic syndrome, and diabetes alone compared with metabolic syndrome alone. The mean heart rate in patients with diabetes was 74.5 beats per min compared with 73.4 beats per min in nondiabetics (P ¼ 0.006 after adjustment for age, sex, b-blocker use and metabolic syndrome). The mean heart rate in patients with metabolic syndrome was 75.4 beats per min compared with 72.6 beats per min in patients with no metabolic syndrome (Po0.0001 after adjustment for age, sex, b-blocker use, and diabetes).
All pairwise comparisons between groups for pulse pressure were significant, except for diabetes alone compared with no diabetes or metabolic syndrome, and diabetes with metabolic syndrome compared with metabolic syndrome alone. There was no difference in pulse pressure between patients with diabetes (57.9 mm Hg) and patients with no diabetes (57.5 mm Hg) after adjustment for age, sex, b-blocker use and metabolic syndrome. Conversely, the difference in pulse pressure between patients with metabolic syndrome (59.5 mm Hg) and with no metabolic syndrome (55.8 mm Hg) was highly significant (Po0.0001 after adjustment for age, sex, b-blocker or calcium antagonist use and diabetes).
DISCUSSION
These results indicate that in hypertensive outpatients, the presence of metabolic syndrome is associated with increased heart rate and pulse pressure. As reported previously, around 30% of treated hypertensive patients in Europe had their blood pressure controlled to levels recommended by European Society of Hypertension/European Society of Cardiology guidelines, 13 leaving patients at unnecessary cardiovascular risk. Given the importance of heart rate and pulse pressure as cardiovascular risk factors, these data further underscore the existing gap between clinical practice and guideline recommendations.
Available data show that the presence of metabolic syndrome in hypertensive patients increases the risk of clinical cardiovascular events or cardiovascular disease, with a twofold increased incidence of cardiovascular events when compared with patients without metabolic syndrome (3.23 vs 1.76 per 100 patient-years, Po0.001). 24 Moreover, several reports show that metabolic syndrome is associated with increased prevalence of hypertensive target organ damage, left ventricular hypertrophy, kidney dysfunction, cardiovascular disease (including myocardial infarction, angina, heart failure, stroke and intermittent claudication), vascular damage and microalbuminuria. [25] [26] [27] [28] [29] [30] The results of our survey are in line with these data, and we suggest a possible association between the increased prevalence of target organ damage and increased pulse pressure and heart rate in our patients with concomitant hypertension and metabolic syndrome, who also were younger that patients without metabolic syndrome.
It is important to note that the association of metabolic syndrome with increased pulse pressure and heart rate was not significantly affected by the concomitant presence of diabetes. Moreover, it was not affected by treatment, as b-blocker use was higher in patients with metabolic syndrome and even more so in patients with both metabolic syndrome and diabetes. Despite the negative chronotropic effect of b-blockers, resting heart rate was higher in these two groups, possibly related to the known association between heart rate and obesity. 13, 15 In patients with Figure 1 . Heart rate (mean±standard error) adjusted for age, sex, and b-blocker use in patients with no metabolic syndrome or diabetes (|MS |DM), with diabetes but no metabolic syndrome (|MS DM), with metabolic syndrome but no diabetes (MS |DM), and with metabolic syndrome and diabetes (MS þ DM). Difference between groups, Po0.0001; * significant difference between pairs. heart failure, greater sympathetic nerve activity has been reported in those with metabolic syndrome compared with those with no metabolic syndrome, with waist circumference and body mass index being closely related to variables to sympathetic activation. 31 Our results cannot be ascribed to age, as the mean age of the patients with metabolic syndrome was lowest compared with the other groups. This supports the suggestion that there is premature senescence of large arteries in the presence of metabolic syndrome. 7 Increased pulse pressure and heart rate may contribute, at least in part, in explaining the increased cardiovascular risk attributed to the presence of metabolic syndrome.
The findings of the present pan-European survey of an association between increased heart rate and diabetes, and the presence of metabolic syndrome in hypertensive outpatients supports the findings of a recently published study in Japan, which reported a linear and significant relationship between heart rate and a cluster of cardiometabolic risk factors in the general population. 32 Higher baseline heart rate predicted the development of obesity, diabetes and insulin resistance in participants examined 20 years later. 32 There is increasing awareness of the association between metabolic syndrome and increased cardiovascular risk. Metabolic syndrome is a major health challenge and the incidence, particularly in middle-aged individuals is increasing. 33, 34 Moreover, our study supports the association of metabolic syndrome with increased heart rate and pulse pressure. 15 Increased heart rate may reflect overweight/obesity and a sedentary lifestyle, in addition to sympathovagal imbalance towards an increased sympathetic tone that has been repeatedly shown as a marker of increased cardiovascular risk. 2, 12 However, it is recognized that autonomic balance evaluation is much more complex than the assessment of baseline heart rate and blood pressure.
Metabolic syndrome has been related to the prevalence of hypertensive target organ damage, left ventricular hypertrophy, kidney dysfunction, cardiovascular disease, vascular damage and microalbuminuria. 25, 28 The increased heart rate and pulse pressure observed in patients with metabolic syndrome may at least in part reflect increased arterial stiffness and increased sympathetic tone.
Limitations of the study This cross-sectional survey was aimed at analyzing the 'real world' situation in European outpatients, and it was not feasible to gather complete detailed data on cardiac or arterial target organ damage. Therefore, the presented data cannot investigate the possible mechanism(s) responsible for the increase in heart rate and pulse pressure in hypertensive subjects with metabolic syndrome. Among the other possibilities, the observed results may be related to an increase in the sympathetic tone, which have been repeatedly observed in patients with metabolic syndrome. These results may well set the stage for further analyses on the topic.
CONCLUSIONS
Our results indicate that in hypertensive outpatients, the presence of metabolic syndrome is associated with increased heart rate and pulse pressure. Among the other possibilities, the increased heart rate and pulse pressure observed in our patients with metabolic syndrome may at least in part reflect target organ damage, with increased arterial stiffness and increased sympathetic tone, and may contribute, to some extent, in explaining the increased cardiovascular risk attributed to the presence of metabolic syndrome. These results are relevant to the real-life situation in everyday clinical practice in Europe, given the specific nature of the GOOD survey.
What is known about this topic
Resting heart rate has been shown as a predictor of total mortality and cardiovascular mortality in the general population, in CAD, and in hypertensive patients. Pulse pressure is also a risk factor, probably as a marker of central artery stiffness, and it has been suggested that lowering pulse pressure may be a useful predictor of the effectiveness of antihypertensive drug therapy. In hypertensive patients, the extent of blood pressure control is adversely influenced by the presence of metabolic syndrome and/or type 2 diabetes.
What this study adds Pulse pressure and heart rate profile was evaluated in a large cohort (n ¼ 3370) of hypertensive 'real-world' outpatients in 12 countries across Europe, demonstrating that the presence of metabolic syndrome is associated with increased heart rate and pulse pressure, independent of the concomitant presence of diabetes or b-blocker treatment.
Increased pulse pressure and heart rate may contribute, at least in part, in explaining the increased cardiovascular risk attributed to the presence of metabolic syndrome.
CONFLICT OF INTEREST
Dr Naditch-Brû lé declares to be an employee of Sanofi-Aventis. All other authors have attended advisory boards and have held lectures for a number of pharmaceutical companies including the sponsor.
